U.S. Trade Distributors Stock News

Cboe Global Markets recently reported past first-quarter 2026 results showing revenue of US$1,272.8 million and net income of US$385.7 million, with earnings per share rising sharply year over year. Alongside record revenue and profits, the company announced a workforce reduction of 20% and plans to exit or sell Cboe Canada and Cboe Australia to concentrate on higher-growth derivatives and data businesses. We’ll now examine how Cboe’s record earnings and major realignment toward core...

Vornado Realty Trust (VNO) opened 2026 with Q1 funds from operations of US$106.3 million, or US$0.56 FFO per share, with the stock trading around US$30.26. Over the last few quarters, the company has reported quarterly revenue between US$448.4 million and US$487.8 million, while basic EPS moved between US$0.003 and US$3.87. This performance came alongside trailing 12 month net income of US$842.9 million and a net margin of 45.2%, supported by a large one off gain of US$925.2 million. For...

Blue Bird (NasdaqGM:BLBD) has appointed Steve Girardin to its board of directors. The appointment follows Blue Bird’s acquisition of full ownership of the Micro Bird joint venture. The move consolidates Blue Bird’s position in the school bus market and updates its board agreement and related party disclosures. For investors tracking the school transportation sector, Blue Bird is a focused player in the design and manufacturing of school buses, with an emphasis on North America. Bringing...

If you are wondering whether Bitmine Immersion Technologies at US$23.10 is still offering value or if the best opportunity has already passed, this breakdown will help you frame the stock in valuation terms instead of just headlines. The stock has been volatile, with a 7.5% return over the last week, 18.8% over the last month, a 25.9% decline year to date, and a 175.1% return over the last year. Recent market interest in Bitmine Immersion Technologies has been shaped by ongoing attention to...

Dorman Products (DORM) opened 2026 earnings season with Q1 numbers set against a recent run of steady results, including Q4 2025 revenue of US$537.9 million and basic EPS of US$0.38 on net income of US$11.6 million. Over the last six reported quarters, revenue has ranged between US$503.8 million and US$543.7 million while quarterly basic EPS has moved from US$1.77 to US$2.50, framing a business that has been consistently profitable. With a trailing 12 month net profit margin of 9.6% and...

In late April 2026, partner GSK announced that the FDA accepted for Priority Review the New Drug Application for bepirovirsen, an antisense therapy for chronic hepatitis B licensed from Ionis, while Ionis also raised its 2026 total revenue guidance to US$875 million–US$900 million and reported first-quarter revenue of US$246.09 million with a reduced net loss of US$92.53 million. Together, the expedited regulatory path for bepirovirsen and Ionis’ higher full-year revenue outlook highlight...

In April 2026, Cypress Grove, Make Time Wellness and Pure Genius Protein each announced new distribution deals with Target, bringing premium goat cheeses, women’s wellness supplements and functional protein beverages into hundreds of Target stores and onto Target.com across major U.S. markets. These partnerships deepen Target’s role as a one-stop destination for specialty food and wellness products, enriching its assortment in higher-margin, trend-focused categories that can support its...

Event context and recent stock performance Amneal Pharmaceuticals (AMRX) has drawn investor attention after recent share price moves, with the stock showing gains over the past week and month alongside a negative return over the past 3 months. For context, Amneal’s 1-day return is about 2.3%, with roughly 5.3% over the past week and 7.5% over the past month, compared with a 7.1% decline over the past 3 months and a 5.9% gain year to date. See our latest analysis for Amneal...

This article examines whether Merck, at around US$113 per share, still offers value or if most of the upside is already reflected in the price, by breaking down what the current valuation signals may be indicating. The stock has returned 2.8% over the last 7 days, is down 6.4% over the past 30 days, is up 6.3% year to date, and has delivered 48.4% over the past year. These moves may have influenced how the market views its risk and reward profile. Recent coverage has focused on Merck as a...

If you are wondering whether DHT Holdings at around US$19.10 is still good value or already pricing in a lot of optimism, the starting point is to look closely at what the market is paying for its fundamentals. The stock has recently posted returns of 4.4% over 7 days, 2.4% over 30 days, 62.7% year to date and 83.0% over the last year. This naturally raises questions about how much of the story is already reflected in the price. Recent news coverage has focused on DHT Holdings in the context...

In late April 2026, TriMas Corporation reported first-quarter 2026 results showing year-over-year sales growth to US$168.28 million, while also reaffirming its full-year 2026 outlook for modest sales growth, adjusted operating margin improvement of more than 300 basis points, and diluted earnings loss per share guidance of US$0.34 to US$0.14. Alongside these updates, TriMas maintained its quarterly cash dividend of US$0.04 per share, underscoring management’s intent to pursue cost reductions...

Event context and recent stock performance Amalgamated Financial (AMAL) has drawn fresh attention after recent trading, with the stock closing at $41.35 and showing gains over the past month and past 3 months, as well as a 1 year total return above 40%. See our latest analysis for Amalgamated Financial. The recent 1 day share price return of 1.9% builds on a stronger year, with year to date share price gains alongside a 1 year total shareholder return of 43.0% and a 3 year total shareholder...

Oil States International (OIS) has just posted another quarter of figures that keep the focus squarely on profitability, with Q4 2025 revenue at US$178.5 million and a basic EPS loss of US$2.03 alongside a net income loss of US$117.0 million. Over the past year, the company has seen quarterly revenue range between US$159.9 million and US$178.5 million, while EPS has moved from a profit of US$0.05 in Q1 2025 to the Q4 loss of US$2.03, with trailing 12 month EPS at a loss of US$1.86 on revenue...

Share repurchase program and capital returns Rexford Industrial Realty (REXR) has authorized a new share repurchase program of up to $500 million through April 2028, while also updating investors on completed repurchase tranches and the expiration of a prior plan. Alongside the buyback moves, the company affirmed a second quarter 2026 common dividend of $0.435 per share and approved quarterly cash dividends on its Series B and Series C preferred stock, reinforcing its current capital return...

On April 28, 2026, Palantir announced a three-year partnership with Cleveland-Cliffs to embed artificial intelligence into production planning, order entry, and operational workflows across the steelmaker’s operations. This move highlights Cleveland-Cliffs’ push to digitalize a traditionally asset-heavy business, potentially affecting costs, service levels, and how it competes within the integrated steel industry. Now we’ll examine how Cleveland-Cliffs’ new AI partnership with Palantir could...

In recent weeks, TeraWulf Inc. completed a public offering of 54,510,000 common shares at US$19.00 each to help fund its planned Hawesville, Kentucky data center campus, repay a bridge credit facility, pursue future site acquisitions, and support general corporate needs. This funding, paired with the company’s shift from pure bitcoin mining toward AI and high-performance computing colocation services, underscores a broader repositioning as a diversified digital infrastructure provider. We’ll...

In April 2026, Definium Therapeutics highlighted past progress and future plans for its DT120 ODT (lysergide tartrate) program in major depressive disorder, generalized anxiety disorder, and posttraumatic stress disorder, including multiple upcoming topline data readouts and a planned Phase 3 PTSD study. The company also outlined a patient-centric commercial and reimbursement strategy for DT120 ODT, positioning its proprietary fast-dissolve LSD formulation as a potentially scalable treatment...

WD-40 stock snapshot after recent performance WD-40 (WDFC) has drawn fresh attention after a mixed stretch in the stock, with a 2.5% gain over the past day contrasting with weaker moves over the week and past 3 months. See our latest analysis for WD-40. That 2.5% 1 day share price return to $209.34 comes after a softer patch, with a 7 day share price return of 4.6% and a 90 day share price return of 14.2%. At the same time, the 1 year total shareholder return of 8.7% and 3 year total...

If you are wondering whether Estée Lauder Companies at around US$82.85 is giving you fair value, a discount, or an expensive ticket to future expectations, this breakdown is for you. The stock has returned 7.5% over the last week and 19.9% over the last month, while the 1 year return is 43.8%. However, the 3 year and 5 year returns are 56.5% and 69.8% declines, which raises real questions about how to read the current price. Recent coverage has focused on how the share price has moved...

Why Lear (LEA) is on investors’ radar today Lear (LEA) has drawn fresh attention after recent trading put the stock around $131.65, with returns of about 11% over the past month and roughly flat over the past 3 months. See our latest analysis for Lear. That recent 11.1% 1 month share price return, on top of a 10.99% year to date share price return and 57.31% 1 year total shareholder return, points to momentum building after a softer 3 month patch. If you are curious about where else capital...

Apple Hospitality REIT’s Q1 2026 Earnings Snapshot Apple Hospitality REIT (APLE) opened 2026 with Q1 Funds From Operations of US$76.5 million and trailing 12 month net profit margins of 12.4%, while the stock trades around US$13.61. Over the past reported quarters, revenue has moved from US$333.0 million in Q4 2024 to US$327.7 million in Q1 2025 and US$326.4 million in Q4 2025, alongside basic EPS readings between US$0.12 and US$0.27 and trailing 12 month FFO in the US$359.2 million range...

Ligand Pharmaceuticals recently raised its 2026 revenue guidance to a range of US$270 million to US$310 million and discussed its planned acquisition of XOMA Royalty, while also participating in several investor conferences, including the H.C. Wainwright Royalty Company Virtual Conference on May 6, 2026. This combination of higher guidance, an expanded royalty portfolio through the proposed XOMA Royalty acquisition, and active investor outreach could reshape how investors view Ligand’s...

Why Protagonist Therapeutics Stock Is Back in Focus Protagonist Therapeutics (PTGX) is in the spotlight after FDA approval of ICOTYDE for moderate to severe plaque psoriasis, a Priority Review for rusfertide, and a Takeda opt out that triggers substantial payments. See our latest analysis for Protagonist Therapeutics. Despite the recent pullback, with a 1-month share price return of 4.4% and a 7-day share price return of 2%, Protagonist Therapeutics still has a 90-day share price return of...

Progressive (NYSE:PGR) is expanding its UpPayment program to offer larger down payment assistance for first-time homebuyers. The initiative aims to support hundreds of eligible applicants as part of a broader push to make homeownership more accessible. The program expansion is positioned within Progressive's wider homeownership and community engagement efforts. Progressive, trading at around $197.74, is drawing attention not for its share price moves but for this new push into direct...